Our top pick for
Synopsys, Inc is a software—infrastructure business based in the US. Synopsys shares (SNPS) are listed on the NASDAQ and all prices are listed in US Dollars. Synopsys employs 13,896 staff and has a trailing 12-month revenue of around USD$3.5 billion.
Since the stock market crash in March caused by coronavirus, Synopsys's share price has had significant positive movement.
Its last market close was USD$226.48, which is 34.06% up on its pre-crash value of USD$149.33 and 115.90% up on the lowest point reached during the March crash when the shares fell as low as USD$104.9.
If you had bought USD$1,000 worth of Synopsys shares at the start of February 2020, those shares would have been worth USD$722.48 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,508.36.
|Latest market close||USD$226.48|
|52-week range||USD$104.9 - USD$232.74|
|50-day moving average||USD$213.3897|
|200-day moving average||USD$188.8189|
|Wall St. target price||USD$232.57|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$4.039|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-14)||N/A|
|1 month (2020-10-23)||-0.11%|
|3 months (2020-08-25)||4.77%|
|6 months (2020-05-22)||32.36%|
|1 year (2019-11-22)||67.29%|
|2 years (2018-11-21)||161.34%|
|3 years (2017-11-22)||153.50%|
|5 years (2015-11-21)||N/A|
Valuing Synopsys stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Synopsys's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Synopsys's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Synopsys shares trade at around 56x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Synopsys's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.9104. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Synopsys's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Synopsys's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$758.1 million.
The EBITDA is a measure of a Synopsys's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$3.5 billion|
|Operating margin TTM||17.18%|
|Gross profit TTM||USD$2.7 billion|
|Return on assets TTM||5.46%|
|Return on equity TTM||14.7%|
|Market capitalisation||USD$34.1 billion|
TTM: trailing 12 months
There are currently 1.7 million Synopsys shares held short by investors – that's known as Synopsys's "short interest". This figure is 13.3% up from 1.5 million last month.
There are a few different ways that this level of interest in shorting Synopsys shares can be evaluated.
Synopsys's "short interest ratio" (SIR) is the quantity of Synopsys shares currently shorted divided by the average quantity of Synopsys shares traded daily (recently around 827048.57142857). Synopsys's SIR currently stands at 2.1. In other words for every 100,000 Synopsys shares traded daily on the market, roughly 2100 shares are currently held short.
However Synopsys's short interest can also be evaluated against the total number of Synopsys shares, or, against the total number of tradable Synopsys shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Synopsys's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Synopsys shares in existence, roughly 10 shares are currently held short) or 0.013% of the tradable shares (for every 100,000 tradable Synopsys shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Synopsys.
Find out more about how you can short Synopsys stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Synopsys.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 21.54
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Synopsys's overall score of 21.54 (as at 10/01/2020) is excellent – landing it in it in the 14th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Synopsys is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 9.6/100
Synopsys's environmental score of 9.6 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Synopsys is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.57/100
Synopsys's social score of 14.57 puts it squarely in the 9th percentile of companies rated in the same sector. This could suggest that Synopsys is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 9.87/100
Synopsys's governance score puts it squarely in the 9th percentile of companies rated in the same sector. That could suggest that Synopsys is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||21.54|
|Total ESG percentile||14.2|
|Environmental score percentile||9|
|Social score percentile||9|
|Governance score percentile||9|
We're not expecting Synopsys to pay a dividend over the next 12 months.
Synopsys's shares were split on a 2:1 basis on 24 September 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Synopsys shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Synopsys shares which in turn could have impacted Synopsys's share price.
Over the last 12 months, Synopsys's shares have ranged in value from as little as $104.9 up to $232.74. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Synopsys's is 1.15. This would suggest that Synopsys's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. It offers Fusion Design Platform, a digital design implementation solution; Verification Continuum Platform that provides virtual prototyping, static and formal verification, simulation, emulation, field-programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. The company also offers intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, SATA, MIPI, HDMI, and Bluetooth low energy applications; analog IP, including data converters and audio codecs; and system-on-chip infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating point components, and ARM AMBA interconnect fabric and peripherals. In addition, it provides logic libraries and embedded memories; configurable processor cores and application-specific instruction-set processor tools for embedded applications; IP subsystems for audio, sensor, and data fusion functionality; and security IP solutions. Further, the company offers Platform Architect tools for SoC architecture analysis and optimization; virtual prototyping solutions; and HAPS FPGA-based prototyping systems, as well as a series of tools used in the design of optical systems and photonic devices. Additionally, it provides security testing, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle; manufacturing solutions; and professional and other services. The company was founded in 1986 and is headquartered in Mountain View, California.
Everything we know about the NewRez IPO, plus information on how to buy in.
Everything we know about the Perella Weinberg IPO, plus information on how to buy in.
Everything we know about the Nanobiotix IPO, plus information on how to buy in.
Everything we know about the Diversey IPO, plus information on how to buy in.
Everything we know about the Certara IPO, plus information on how to buy in.
Everything we know about the Arrival IPO, plus information on how to buy in.
Everything we know about the iSpecimen IPO, plus information on how to buy in.
Everything we know about the IDEX Biometrics ASA IPO, plus information on how to buy in.
Steps to owning and managing MYSZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing MG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.